Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ESAB
ESAB logo

ESAB Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy ESAB Corp (ESAB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
98.930
1 Day change
-2.45%
52 Week Range
137.420
Analysis Updated At
2026/04/10
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

ESAB Corp is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. While the company has positive catalysts like reaffirmed revenue guidance and CFO appointment, the financial performance shows declining net income, EPS, and gross margin. Additionally, insider selling and a lack of strong trading signals suggest caution. Holding the stock or waiting for better entry points is recommended.

Technical Analysis

The MACD is positive and expanding, suggesting bullish momentum. RSI is neutral at 62.399, and moving averages are converging, indicating no strong trend. The stock is trading near resistance at R1: 102.131, with limited upside potential in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
1

Positive Catalysts

  • Appointment of R. Brent Jones as CFO, reaffirmed 2026 revenue and EBITDA guidance, improved market conditions due to U.S.-Iran ceasefire.

Neutral/Negative Catalysts

  • Declining financial metrics (net income, EPS, gross margin), significant insider selling, and mixed analyst sentiment with lowered price targets.

Financial Performance

In Q4 2025, revenue increased by 7.49% YoY to $720.99M, but net income dropped by 29.35% YoY to $37M. EPS fell by 30.23% YoY to 0.6, and gross margin declined by 7.14% to 35.76%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain a Buy rating but have lowered price targets recently, citing challenges like high leverage, Q4 miss, and fiscal 2026 guidance requiring acceleration. However, they acknowledge ESAB's strong international position and potential growth opportunities in North America.

Wall Street analysts forecast ESAB stock price to rise
5 Analyst Rating
Wall Street analysts forecast ESAB stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 101.410
sliders
Low
140
Averages
144.8
High
150
Current: 101.410
sliders
Low
140
Averages
144.8
High
150
DA Davidson
Buy
downgrade
$146 -> $142
AI Analysis
2026-04-16
New
Reason
DA Davidson
Price Target
$146 -> $142
AI Analysis
2026-04-16
New
downgrade
Buy
Reason
DA Davidson lowered the firm's price target on ESAB to $142 from $146 and keeps a Buy rating on the shares. The Iran conflict and higher oil prices negatively impacted demand for ESAB solutions, necessitating the firm's lowered estimates for Q1, even though the firm's checks indicated an improving US market, which is likely to further accelerate as 2026 progresses, the analyst tells investors in a research note. Roth is still cutting its FY26 EPS view by 7c to $5.74.
Oppenheimer
Bryan Blair
Outperform
to
Outperform
downgrade
$148 -> $140
2026-04-14
New
Reason
Oppenheimer
Bryan Blair
Price Target
$148 -> $140
2026-04-14
New
downgrade
Outperform
to
Outperform
Reason
Oppenheimer analyst Bryan Blair lowered the firm's price target on ESAB to $140 from $148 and keeps an Outperform rating on the shares. With ESAB down 19% since the start of the Iran war, eventual Middle East rebuild supplementing a powerful set of core growth catalysts, and the close of growth/margin-enhancing Eddyfi on the horizon, the firm sees a compelling buying opportunity on shares. Although Oppenheimer recognizes lingering tactical risks, the firm remains confident in ESAB's positioning for core EPS inflection during the second half of the year with Eddyfi strengthening the team's profitable growth trajectory into 2027. And given that setup, it also sees valuation as a legitimate catalyst.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ESAB
Unlock Now

People Also Watch